Litigation Details for In Re: Byrn (D. Del. 2023)
✉ Email this page to a colleague
In Re: Byrn (D. Del. 2023)
Docket | ⤷ Sign Up | Date Filed | 2023-04-12 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 10,039,745; 10,154,987; 11,141,405; 8,568,747; 9,669,008; 9,808,442 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in In Re: Byrn
Details for In Re: Byrn (D. Del. 2023)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2023-04-17 | 11 | Exhibit B | of Azurity’s Epaned® patents (U.S. Patent Nos. 9,669,008, 9,808,442, 10,039,745, 10,154,987, 10,772,868… "'442 patent"), 10,039,745 (the "'745 patent"), and 10,154,987 (the …case are United States Patent Nos. 10,039,745 (the "'745 patent") and 10,154,987 (the…infringes claims 4, 7, and 10 of U.S. Patent No. 10,039,745 (“the ’745 Patent”). 2. Judgment is…s U.S. Patent Nos. 9,669,008, 9,808,442, 10,039,745, and 10,154,987 (“the First Wave Patents”); | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |